 |
 |
|
Please send comments,
questions, and suggestions
about Oberlin Online news
and feature articles to
online.news@oberlin.edu.
NEW HORIZONS IN CANCER THERAPIES:
A SYMPOSIUM AT OBERLIN COLLEGE NOVEMBER 8
NOVEMBER 1, 2001-- "New Horizons in Cancer Therapies" is the title of a symposium that will take place in Oberlin College's new science center on Thursday, November 8 at 8:00 P.M. Four alumni, all highly respected leaders in their fields, will return to campus to discuss new advances in cancer research.
The panel includes Harlan Waksal, Class of '75, Executive Vice President and Chief Operating Office, ImClone Systems Incorporated; David Ranney, Class of '65, Managing Director, Global BioMedical Solutions; Herbert Morse, Class of '65, Chief, Laboratory of Immunopathology, National Institute of Allergy and Infectious Diseases; Raphael Pollock, Class of '72, Division Head, Surgical Oncology, MD Anderson Cancer Center and Robin Treichel, Associate Professor of Biology, who will be the facilitator.
ImClone Systems Inc., co-founded by Waksal, was highlighted in a recent article in Business Week (July 9, 2001) regarding the company's role in producing C225, a new cancer treatment drug that was granted fast-track approval status by the Food and Drug Administration last February. Waksal will discuss C225 and other new drugs breaking ground in cancer treatment.
Ranney will discuss the delivery of system of cancer treatments and how drugs reach and attack tumors. Morse will focus on the underlying causes of cancers, while Pollock will bring his expertise as a practicing surgeon to the discussion.
The symposium is free and open to the public and is sponsored by the biology department, the alumni association and the Mead-Swing Lecture Committee.
Media Contact: Scott Wargo
       |